Form 4: Prelude Therapeutics CEO Krishna Vaddi Reports Stock Purchases
SEC Form 4
CEO Krishna Vaddi reports purchasing Prelude Therapeutics Inc. (PRLD) stock in multiple transactions.
Summary
- Krishna Vaddi, CEO of Prelude Therapeutics Inc. (PRLD), filed a Form 4 disclosing recent transactions in the company's stock.
- On March 14, 2025, Vaddi purchased 29,999 shares of common stock at a weighted average price of $0.7544 per share.
- On March 17, 2025, Vaddi purchased 9,106 shares of common stock at a weighted average price of $0.7499 per share.
- Following these transactions, Vaddi directly owns 1,303,880 shares of Prelude Therapeutics Inc.
- Vaddi also indirectly owns shares through various trusts and ventures, including Dolphin City Trust (423,655 shares), Brocade Trust (551,774 shares), Blue Sky Trust (551,776 shares), and Sidus Ventures LLC (142,553 shares).
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CEO's stock purchases, which can be interpreted as a sign of confidence in the company's future.
Positives
- The CEO's purchase of company stock may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- The CEO's stock purchases could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| February 3, 2025 | Date of Power of Attorney execution. |
| March 14, 2025 | Date of first reported stock purchase. |
| March 17, 2025 | Date of second reported stock purchase. |
| March 18, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.